NASDAQ:AKCA - Akcea Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $18.15
  • Forecasted Upside: -0.11 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$18.17
+0.30 (1.20%)
Get New Akcea Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AKCA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AKCA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$18.15
▼ -0.11% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Akcea Therapeutics in the last 3 months. The average price target is $18.15, with a high forecast of $18.15 and a low forecast of $18.15. The average price target represents a -0.11% upside from the last price of $18.17.

Hold

The current consensus among 3 polled investment analysts is to hold stock in Akcea Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/1/2020BMO Capital MarketsLower Price Target$26.00 ➝ $18.15Low
i
8/31/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$26.00 ➝ $18.15Low
i
8/31/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal WeightHigh
i
8/9/2020CowenReiterated RatingHoldLow
i
2/26/2020CowenReiterated RatingHoldHigh
i
1/29/2020Needham & Company LLCReiterated RatingBuy$41.00Low
i
Rating by Chad Messer at Needham & Company LLC
1/22/2020Needham & Company LLCReiterated RatingBuy$41.00Medium
i
Rating by Chad Messer at Needham & Company LLC
11/6/2019CowenReiterated RatingHoldHigh
i
11/6/2019Needham & Company LLCReiterated RatingBuy$45.00High
i
10/8/2019BMO Capital MarketsLower Price TargetOutperform$43.00 ➝ $39.00Medium
i
Rating by Do Kim at BMO Capital Markets
10/7/2019Needham & Company LLCReiterated RatingBuy$45.00High
i
10/7/2019Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformHigh
i
9/23/2019CowenReiterated RatingHoldHigh
i
9/23/2019Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$44.00 ➝ $24.00High
i
8/7/2019BMO Capital MarketsSet Price TargetBuy$43.00Low
i
Rating by Do Kim at BMO Capital Markets
9/25/2018Stifel NicolausBoost Price TargetHold ➝ Hold$25.00 ➝ $31.00High
i
9/18/2018Needham & Company LLCInitiated CoverageBuy ➝ Buy$45.00High
i
9/2/2018CowenReiterated RatingHoldLow
i
8/28/2018Stifel NicolausLower Price TargetHold ➝ Hold$33.00 ➝ $25.00High
i
8/8/2018UBS GroupDowngradeBuy ➝ HoldLow
i
8/7/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$38.00 ➝ $40.00High
i
8/7/2018Wells Fargo & CompanyBoost Price TargetOutperform$33.00 ➝ $46.00High
i
8/7/2018Stifel NicolausReiterated RatingHold$33.00High
i
5/11/2018Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformHigh
i
5/4/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$42.00 ➝ $38.00N/A
i
3/19/2018Wells Fargo & CompanyReiterated RatingOutperform ➝ Market Perform$20.00High
i
3/16/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$20.00 ➝ $30.00High
i
3/15/2018Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformHigh
i
2/27/2018BMO Capital MarketsBoost Price TargetPositive ➝ Outperform$25.00 ➝ $30.00High
i
2/27/2018Stifel NicolausDowngradeBuy ➝ Hold$20.00High
i
2/27/2018CowenDowngradeOutperform ➝ Market PerformHigh
i
2/27/2018Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$27.00High
i
11/7/2017Stifel NicolausReiterated RatingBuy ➝ Buy$19.00 ➝ $20.00N/A
i
10/31/2017CowenReiterated RatingBuyN/A
i
8/8/2017BMO Capital MarketsInitiated CoverageOutperform$25.00Medium
i
8/8/2017Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$27.00Medium
i
8/8/2017CowenInitiated CoverageOutperformMedium
i
8/8/2017Stifel NicolausInitiated CoverageBuy ➝ Buy$19.00Medium
i
(Data available from 6/14/2016 forward)
Akcea Therapeutics logo
Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.
Read More

Today's Range

Now: $18.17
$18.17
$18.17

50 Day Range

MA: $18.16
$18.13
$18.17

52 Week Range

Now: $18.17
$8.00
$21.70

Volume

N/A

Average Volume

361,806 shs

Market Capitalization

$1.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Akcea Therapeutics?

The following sell-side analysts have issued stock ratings on Akcea Therapeutics in the last year: BMO Capital Markets, Cowen Inc, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for AKCA.

What is the current price target for Akcea Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Akcea Therapeutics in the last year. Their average twelve-month price target is $18.15, suggesting a possible downside of 0.1%. BMO Capital Markets has the highest price target set, predicting AKCA will reach $18.15 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $18.15 for Akcea Therapeutics in the next year.
View the latest price targets for AKCA.

What is the current consensus analyst rating for Akcea Therapeutics?

Akcea Therapeutics currently has 3 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AKCA, but not buy more shares or sell existing shares.
View the latest ratings for AKCA.

What other companies compete with Akcea Therapeutics?

How do I contact Akcea Therapeutics' investor relations team?

Akcea Therapeutics' physical mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company's listed phone number is 617-207-0202 and its investor relations email address is [email protected] The official website for Akcea Therapeutics is www.akceatx.com.